Wei-Hsun Hsu
Overview
Explore the profile of Wei-Hsun Hsu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
393
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang C, Liao W, Ho C, Chen K, Tsai T, Hsu C, et al.
J Formos Med Assoc
. 2024 Dec;
PMID: 39694766
Background: PD-L1 is associated with poor efficacy of first- or second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in untreated EGFR-mutant non-small-cell lung cancer (NSCLC). Whether PD-L1 is...
2.
Lin Y, Ho C, Hsu W, Liao W, Yang C, Yu C, et al.
Cancer Med
. 2023 Dec;
13(1):e6870.
PMID: 38140788
Introduction: According to current International Association for the Study of Lung Cancer guideline, physicians may first use plasma cell-free DNA (cfDNA) methods to identify epidermal growth factor receptor (EGFR) tyrosine...
3.
Huang D, Liao B, Hsu W, Yang C, Lin Y, Wu S, et al.
Oncology
. 2023 Oct;
102(4):318-326.
PMID: 37778345
Introduction: In real-world practice, most non-small cell lung cancer (NSCLC) patients receiving combined immunochemotherapy are exposed to short-course corticosteroids following immune checkpoint inhibitor (ICI) infusion to prevent chemotherapy-related adverse events....
4.
Yang C, Shih J, Liao W, Ho C, Hsu C, Tsai T, et al.
Eur J Cancer
. 2023 Sep;
193:113310.
PMID: 37722270
Background: Next-generation sequencing (NGS) of plasma cell-free DNA identifies driver mutations in advanced non-small cell lung cancer (NSCLC) and may complement routine molecular evaluation. The utility of liquid NGS at...
5.
Chan H, Hsu W, Chen J, Lee J
J Formos Med Assoc
. 2023 Aug;
123(2):273-282.
PMID: 37633771
Background/purpose: Patients with advanced cancer sometimes travel to locations that have the treatment that they need. We explored the prognostic factors of survival in patients with advanced lung cancer who...
6.
Chow Y, Hsu W, Chen M, Lin W, Chiu A
Urology
. 2023 Feb;
175:216-222.
PMID: 36805415
Objective: To treat intractable hematuria with intravesical instillation of epinephrine. Methods: Sixty patients were treated with intravesical instillation of epinephrine at Mackay Memorial Hospital. The control group was composed of...
7.
Wang M, Yang J, Mitchell P, Fang J, Camidge D, Nian W, et al.
Cancer Discov
. 2022 Apr;
12(7):1676-1689.
PMID: 35404393
Significance: We report the discovery and early clinical development of sunvozertinib, a potential treatment option for the unmet medical need of EGFRexon20ins NSCLC. This article is highlighted in the In...
8.
Silveira P, Kupresanin F, Romano A, Hsu W, Lo T, Ju X, et al.
Front Immunol
. 2022 Feb;
13:784528.
PMID: 35222372
Antibodies targeting the activation marker CD83 can achieve immune suppression by targeting antigen-presenting mature dendritic cells (DC). This study investigated the immunosuppressive mechanisms of anti-CD83 antibody treatment in mice and...
9.
Liao B, Hsu W, Lee J, Yang C, Tsai T, Liao W, et al.
JTO Clin Res Rep
. 2021 Sep;
2(1):100099.
PMID: 34589970
Introduction: Recent advances in the detection of genomic DNA from plasma samples allow us to follow tumor DNA shedding in plasma during systemic treatment. Osimertinib is the standard of care...
10.
Hsu C, Yang A, Chen J, Tsai H, Lin S, Tai P, et al.
Cancers (Basel)
. 2021 Jan;
13(2).
PMID: 33450879
Epidermal growth factor receptor () mutations are the most common driver genes in non-small cell lung cancer (NSCLC), especially in the Asian population. Although EGFR-tyrosine kinase inhibitors (TKIs) are influential...